Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Blood red petri-dish in the hand of a researcher with bacterial colonies grown on the plate.

Prof Paresh Vyas and his team are investigating haematopoietic stem cells (HSCs) and clonal haematopoiesis (CH), associated with cardiovascular disease and blood cancers. They have been collecting bone marrow samples from otherwise well patients having hip-replacement operations to further understand the mechanisms involved to help develop targeted therapies.

More recently the team have also been studying patients with COVID-19, to understand if CH has an impact on the clinical course of COVID-19. Find out more about this research on the Cancer Research UK Oxford Centre's website.

Similar stories

Research unpicks why immune responses decrease with age

MRC MHU

Study reveals what happens to blood cell production during the ageing process, which could help identify new therapeutic targets.

Study finds new human blood disorder

MRC MHU RDM

The Patel Group have discovered a new human disease caused by formaldehyde accumulation in cells

Interferon-b trial shows positive results

COVID-19 MRC HIU NDM

A trial of a new inhaled antiviral drug for COVID-19 has shown positive results and the drug is now moving into a larger international phase 3 trial of hospitalised patients. MRC HIU's Professor Ling-Pei Ho is one of the main co-authors on the paper.

Researchers target previously unknown ‘genetic vulnerability’ in breast cancer cells

MRC MHU NDM RDM

New Nature paper reveals discovery of a genetic vulnerability in nearly 10% of breast cancer tumours and how this can be targeted to selectively kill cancer cells.

Persistent immune memory of COVID-19 found in recovered patient T cells

COVID-19 MRC HIU NDM RDM

New Nature Immunology paper finds strong T cell responses in recovered COVID-19 patients